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Introduction
Temporal lobe epilepsy (TLE) is the most common form of
partial epilepsy [1] and this disorder is considered to be
polygenic and complex. Various susceptibility genes and
environmental factors are believed to be involved in the
aetiology of TLE and concordance between genotype and
phenotype is relatively weak. To understand the genetic
background of complex diseases, association studies have
been proposed as a method of choice [2]. However, this
approach remains controversial and, in order to avoid false-
positive association, replication of the first case-control
study in independent groups of patients is recommended
[3]. Recently a number of groups, including our own, have
reported non-replications between several putative suscep-
tibility genes and TLE [1, 4]. 
Since several other studies have reported an associa-
tion between common variants in specific genes and
TLE, our aim, in the present study, is to replicate them:
apolipoprotein E (ApoE) [5], interleukin 1α (IL-1α),
interleukin 1β (IL-1β), interleukin 1RA (IL-1RA) [6] and
prodynorphin (PDYN) [7].
Methods
Subjects
Our study group consisted of 109 unrelated patients with
a diagnosis of non-lesional TLE. They were admitted
under partial epilepsy criteria in the epilepsy unit of the
university hospital of Montpellier (France). These
patients suffered from a severe form of epilepsy with
poor control of their seizures. Poor control is defined as
a failure to respond to two or three single drugs or a com-
Abstract The objective of this study is to replicate previ-
ously published results regarding the involvement of sev-
eral susceptibility genes in temporal lobe epilepsy (TLE):
interleukin 1β (IL-1β), interleukin 1α (IL-1α), interleukin
1RA (IL-1RA), apolipoprotein E (ApoE) and prodynor-
phin (PDYN). We used a case-control approach compar-
ing several polymorphisms within these candidate genes
between unrelated TLE patients and matched controls.
We were thus able to confirm the role of ApoE, IL-1α and
IL-1RA genes in TLE disease, but failed to confirm the
involvement of IL-1β and PDYN. This failure should be
interpreted with caution, as this may be due to the small
size of our study groups and the resultant lack of statisti-
cal power.
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bination of them. Diagnosis was based on patient history,
clinical examination, interictal and ictal EEG analysis
carried out with monitoring video-EEG, and MR evalua-
tion. Demographic and clinical characteristics of our
cohort of TLE patients have been reported in detail in a
previous study [4].
The healthy control group was recruited from blood
donors at the hospital in Geneva. To minimise morbidity
among subjects in this group, only blood donors older
than 35 years and without personal and/or family history
of epilepsy and seizure were included. Patients and con-
trols were European Caucasian for at least two genera-
tions. Written informed consent was obtained from all
participants. The Research Ethics Board of the
Department of Clinical Neurosciences of Geneva
reviewed and approved this study.
Molecular methods
DNA was extracted from peripheral blood leukocytes by
use of the Nucleon BACC 2 kit (Amersham). Genotyping
reactions were carried out as described in the different
studies [6, 8, 9].
Statistical analysis
For our statistical analysis, in addition to the total cohort
of patients, we divided the TLE group into subgroups,
according to the existence or not of familial risk and hip-
pocampal sclerosis. This was done in order to facilitate
comparison between our data and that from analogous
published work. In order to perform case-control genetic
comparisons, differences in genotype and allele frequen-
cies between all TLE, TLE subgroups and healthy con-
trols were analysed by using the Chi-square test: 3 by 2
tables for PDYN, IL-1α and IL-1β; 4 by 2 tables for IL-
1RA. As age at onset displayed a non-parametric curve,
the Mann–Whitney U-test was used in place of the t-test
for the comparison of age at onset and the presence or
absence of the ApoE ε4 allele. We used the statistical
package SPSS V.11.0.
As we compared genotypic and allelic distributions of
various polymorphic markers between healthy and dis-
eased subjects, a Bonferroni correction should be applied to
correct for multiple testing. Adjustments for multiple com-
parisons are recommended to avoid excessively easy rejec-
tion of the null hypothesis. However, reducing the type I
error increases the type II error and therefore increases the
frequency of incorrect statements of no relationship
between two factors. This could thus lead to missing an
association in data that is not the result of chance [10]. The
rejection of the null hypothesis should be considered by
taking into account both the evidence from the data and the
relevance of other explanations. Moreover, our argument is
based on previous findings and should be seen as a confir-
mation of research in the field of TLE. In this present study,
choosing not to penalise ourselves by missing possibly
important findings, we decided not to correct our results for
multiple testing. 
Ethnicity was recorded using a self-reporting ques-
tionnaire including perceived nationality, mother tongue
and ethnicity of the subject together with all four grand-
parents. To reduce the possibility of stratification bias,
we used an average FST between pairs of ethnic popula-
tions between 0.0009 and 0.0048 (table 5.5.1 in ref.
[11]).
Power calculation
Statistical power to detect associations was estimated
using the Genetic Power Calculator
(http://pngu.mgh.harvard.edu/purcell/gpc/). For age at
onset we aimed to detect genetic effects explaining at
least 2% of variance in the trait under an additive genet-
ic model for a polymorphism with a minor allele frequen-
cy of 0.12. Power for detecting such effect was calculat-
ed for the nominal significance level α=0.05. For discrete
traits, power for each study was calculated separately
using an additive model with genetic relative risk of 2
and an α level=0.05.
Results
Throughout our study, genotypic distributions in both
patients and controls were in Hardy–Weinberg equilibri-
um.
Apolipoprotein E
Five studies have been published on ApoE and TLE age
at onset [1, 5, 12–14]. In one of them, a positive associa-
tion was found between early age at onset of the disease
and the presence of ApoE ε4 allele (ε4+: 5±5 years vs.
ε4–: 14.9±10 years; p=0.005) [5]; however, the four other
studies were unable to replicate this positive association.
Our results confirmed a significant association between
an early age at onset of epilepsy and the presence of
allele ε4 (ε4+: 10.54±6.36 years vs. ε4–: 16.51±9.90
years; p=0.003) (Table 1). The study had 99% power to
detect a gene effect, explaining 2% of the variance in the
trait (Table 1).
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Interleukin 1α
Based on pathophysiological hypotheses, several associ-
ation studies have been carried out between interleukin-
related genes and TLE. Two were performed with IL-1α
and both showed no association [6, 15]. 
We partitioned our cohort of patients, like
Kanemoto’s group, based on the existence or non-exis-
tence of a hippocampal sclerosis (TLE-HS+) [6], and
like Ozkara’s team, based on the absence of antecedent
of febrile convulsion (TLE-FC–) [15]. We found a sig-
nificant positive genotypic association between the
whole TLE sample and the promoter IL-1α–889 SNP,
but this was observed in TLE-HS+ patients (Table 2).
However, as shown in Table 2, we did not have enough
power to detect any significant association between
TLE-HS– and controls (power=43%). Given the high
frequency of the 1 allele in this sample (80.4%), an
association could be suspected and further study with
higher number of individuals is warranted.
Interestingly, we also found a positive association
between IL-1α–889 SNP and TLE-FC– (Table 2), but no
statistical difference between TLE-HS+-FC– vs. con-
trols (data not shown).
Interleukin 1RA
IL-1RA is the second interleukin-related gene studied by
Kanemoto et al. [6]. Once again they failed to show any
association. 
We observed significant differences in the allelic and
genotypic frequencies between patients and controls, but
here this concerns TLE-HS– (Table 3). 
Interleukin 1β
In this case, Kanemoto et al. [6] and Ozkara et al. [15]
did not find an association between IL-1β–3953 and
TLE. We were also unable to find any significant statis-
tical difference (Table 4).
In contrast, Kanemoto et al. found a statistically
higher frequency of the IL-1β–511 2-2 genotype in
TLE-HS+ subjects compared to control subjects [6],
and confirmed this result using a larger study group
[16]. However this association was not observed in five
other ethnically variable populations [1, 15, 17–19] or
in our cohort of patients (Table 5).
In addition, we analysed the two IL-1β SNP haplo-
types for the two subgroups of TLE (data not shown)
and again we found no significant association.
However, and as previously stated, negative results
involving the TLE-HS– group should be kept with cau-
tion as power to detect an association is limited.
Prodynorphin
Stogmann et al. reported that PDYN promoter L allele
confers an increased risk for TLE in patients
with a family history of seizures (OR=2.25 (CI
1.41–3.62); p=0.0006) [7]. This result remained uncon-
firmed in three independent Caucasian populations [1,
20, 21].
In the present study, we find a non-significant trend
of excess of the L allele in those patients with a family
history of epilepsy (OR=1.60 (CI 0.82–3.31); p=0.163)
(Table 6). 
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Table 1 ApoE allele and genotype distributions and association between ε4 allele and age at onset
Controls Patients p Age at onset p (Mann–Whitney U-test) Power
of seizures
n (%) n (%) Presence Absence
of ε4 allele of ε4 allele 
Genotype 227 109 NS*
ε2–2 0 (0.0) 0 (0.0)
ε2–3 25 (11.0) 9 (8.3)
ε2–4 5 (2.2) 1 (0.9) n=26 n=80
ε3–3 151 (66.5) 72 (66.1) Age: 10.54±6.36 Age: 16.51±9.90 p=0.003 0.99
ε3–4 43 (18.9) 27 (24.8)
ε4–4 3 (1.3) 0 (0.0)
Allele 454 218 NS*
ε2 30 (6.6) 10 (4.6)
ε3 370 (81.5) 180 (82.6)
ε4 54 (11.9) 28 (12.8)
*NS, non-significant
400 Neurol Sci (2008) 29:397–403
Ta
bl
e 
2
IL
-1
α
–
88
9
al
le
le
 a
nd
 g
en
ot
yp
e 
di
str
ib
u
tio
ns
Co
nt
ro
ls
TL
E
TL
E-
TL
E-
TL
E
p u
d
H
S+
a
H
S–
b
FC
–
c
n
 (%
)
n
 (%
)
n
 (%
)
n
 (%
)
n
 (%
)
TL
E-
H
S+
a
Po
w
er
TL
E-
H
S–
b
Po
w
er
TL
E
Po
w
er
TL
E-
FC
–
c
Po
w
er
v
s.
v
s.
v
s.
v
s.
co
n
tr
ol
s
co
n
tr
ol
s
co
n
tr
ol
s
co
n
tr
ol
s
A
lle
le
47
0
21
8
17
2
46
10
8
0.
05
9
0.
89
0.
06
6
0.
43
0.
01
8
0.
95
0.
07
9
0.
74
1
31
6
16
6
12
9
37
82
.0
(67
.2)
(76
.1)
(75
.0)
(80
.4)
(75
.9)
2
15
4
52
43
9
26
.0
(32
.8)
(23
.9)
(25
.0)
(19
.6)
(24
.1)
G
en
ot
yp
e
23
5
10
9
86
23
54
0.
02
7
0.
10
4
0.
00
78
0.
02
2
1-
1
99
65
50
15
33
(42
.1)
(59
.6)
(58
.1)
(65
.2)
(61
.1)
1-
2
11
8
36
29
7
16
(50
.2)
(33
.1)
(33
.7)
(30
.4)
(29
.6)
2-
2
8
8
7
1
5
(7.
7)
(7.
3)
(8.
1)
(4.
4)
(9.
3)
a T
LE
-H
S+
,
 
TL
E 
w
ith
 h
ip
po
ca
m
pa
l s
cl
er
os
is;
 b T
LE
-H
S–
,
 
TL
E 
w
ith
ou
t h
ip
po
ca
m
pa
l s
cl
er
os
is;
 c T
LE
-F
C–
,
 
TL
E 
w
ith
ou
t a
nt
ec
ed
en
ts 
of
 fe
br
ile
 c
on
v
u
lsi
on
; d
p u
,
 
p
u
n
co
rr
ec
te
d
Ta
bl
e 
3 
IL
-1
RA
 a
lle
le
 a
nd
 g
en
ot
yp
e 
di
str
ib
u
tio
ns
 
Co
nt
ro
ls
TL
E-
H
S+
a
TL
E-
H
S–
b
p u
c
n
 (%
)
n
 (%
)
n
 (%
)
TL
E-
H
S+
a
Po
w
er
TL
E-
H
S–
b
Po
w
er
TL
E-
H
S–
b
Po
w
er
v
s.
 c
o
n
tr
ol
s
v
s.
 c
o
n
tr
ol
s
v
s.
 T
LE
-H
S+
a
G
en
ot
yp
e
24
2
86
23
0.
76
8
0.
95
0.
00
1
0.
51
0.
03
6
0.
64
1-
1
12
8
43
5
(52
.9)
(50
.0)
(21
.7)
1-
2
90
36
13
(37
.2)
(41
.9)
(56
.5)
1-
4
5
1
0
(2.
1)
(1.
2)
(0.
0)
1-
5
0 
(0.
0)
0 
(0.
0)
1 
(4.
3)
2-
2
16
 (6
.6)
6 
(7.
0)
4 
(17
.4)
2-
4
3 
(1.
2)
0 
(0.
0)
0 
(0.
0)
A
lle
le
48
4
17
2
46
0.
52
5
<
0.
00
01
0.
02
2
1
35
1 
(72
.5)
12
3 
(71
.5)
24
 (5
2.2
)
2
12
5 
(25
.8)
48
 (2
7.9
)
21
 (4
5.7
)
4
8 
(1.
7)
1 
(1.
4)
0 
(0.
0)
5
0 
(0.
0)
0 
(0.
0)
1 
(2.
2)
a T
LE
-H
S+
,
 
TL
E 
w
ith
 h
ip
po
ca
m
pa
l s
cl
er
os
is;
 b T
LE
-H
S–
,
 
TL
E 
w
ith
ou
t h
ip
po
ca
m
pa
l s
cl
er
os
is;
 c p
u
,
 
p
u
n
co
rr
ec
te
d
Discussion
In this present paper, we attempt to replicate published
association studies between TLE, and subtypes of this
disease, and several candidate genes. 
Some evidence has implicated ApoE in the hip-
pocampal response to injury. Indeed, astrocytes reply to
neuronal damage by synthesising and releasing ApoE.
Three major isoforms of ApoE have been identified, ε2,
ε3 and ε4 [8]. The ApoE ε4 allele has often been asso-
ciated with neurological diseases and/or their early-age
onset in carriers: Alzheimer’s disease [22], amyotroph-
ic lateral sclerosis [23] and Parkinson’s disease [24].
Although three other TLE association studies were
unable to find such effect [1, 13, 14] and the present
sample size is small, we have enough power to detect a
statistically significant result between an early age at
onset of TLE and the presence of the ε4 allele.
Moreover, the present study is the second one that
reports an early age at onset in ε4 TLE carriers. These
results suggest that TLE is one of the multiple neuro-
logical diseases for which ApoE has a general role in
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Table 4 IL-1β+3953 allele and genotype distributions
Controls TLE-HS+a TLE-HS–b puc
n (%) n (%) n (%) TLE-HS+a Power TLE-HS–b Power
vs. controls vs. controls
Genotype 234 86 23 NSd 0.97 NSd 0.60
1-1 118 (50.4) 45 (52.3) 14 (60.9)
1-2 101 (43.2) 34 (39.5) 8 (34.8)
2-2 15 (6.4) 7 (8.2) 1 (4.3)
aTLE-HS+, TLE with hippocampal sclerosis; bTLE-HS–, TLE without hippocampal sclerosis; cpu, p uncorrected; dNS, non-significant
Table 5 IL-1β–511 allele and genotype distributions
Controls TLE-HS+a TLE-HS–b puc
n (%) n (%) n (%) TLE-HS+a Power TLE-HS–b Power
vs. controls vs. controls
Genotype 227 86 23 NSd 0.98 NSd 0.51
1-1 99 (43.6) 35 (40.7) 12 (52.2)
1-2 108 (47.6) 45 (52.3) 9 (39.1)
2-2 20 (8.8) 6 (7.0) 2 (8.7)
aTLE-HS+, TLE with hippocampal sclerosis; bTLE-HS–, TLE without hippocampal sclerosis; cpu, p uncorrected; dNS, non-significant
Table 6 PDYN allele and genotype distributions
Controls Familial- OR pua Power Nonfamilial- OR pua Power
risk (95% CI) risk (95% CI)
TLE TLE
n (%) n (%) n (%)
Allele 412 42 0.163 0.68 166 NSb 0.98
L 106 15 1.60
(25.7) (35.7) (0.82– 50 
3.31) (30.1) 1.24
(0.84–1.85)
H 306 27 0.62 116 0.80
(74.3) (64.3) (0.32–1.21) (69.9) (0.54–
1.20)
Genotype 206 21 0.32 83 NSb
LL 14 (6.8) 2 (9.5) 1.44 7 (8.4) 1.26 
(0.30–6.83) (0.49–3.25)
LH 78 (37.9) 11 (52.4) 1.81 36 (43.4) 1.26 
(0.73–4.45) (0.75–2.11)
HH 114 (55.3) 8 (38.1) 0.50 (0.20–1.25) 40 (48.2) 0.75 
(0.45–1.25)
apu, p uncorrected; bNS, non-significant
neuronal degeneration or regeneration, rather than a
specific role in their aetiopathogenesis. 
IL-1 shows two structurally distinct forms, IL-1α and
IL-1β, that act on the IL-1 receptor. Interleukin 1 recep-
tor antagonist protein (IL-1RA) acts on the same recep-
tor and inhibits IL-1α and IL-1β binding. IL-1α and IL-
1β are involved in various immune responses, inflamma-
tory processes, apoptosis and haematopoiesis. They are
produced by monocytes and macrophages. Moreover, IL-
1α and IL-1β are also synthesised by glial and neuronal
cells [25]. Their implication in the central nervous sys-
tem was demonstrated by the presence of high-density
IL-1 receptors in molecular and granular layers of den-
tate gyrus [26], suggesting a physiological role for IL-1
in the hippocampus. 
In contrast to Kanemoto et al. [6], we found a positive
association between TLE and IL-1α–889, which is a vari-
ation in the 5’ regulatory region. This result is in agree-
ment with the work of Peltola et al. These authors also
found a significantly higher frequency for IL-1α allele 1
in patients with localisation-related epilepsy, such as
TLE, lobe temporal epilepsy, parieto-occipital epilepsy
and multifocal epilepsy [27]. Despite higher frequencies
of IL-1α allele 1 and genotype 1-1 in all the sub-groups
compared to the controls, only some of them reach sig-
nificance (the whole TLE population and the TLE-HS+
and TLE-FC– sub-groups). This is probably due to a lack
of statistical power and larger groups of patients will be
needed to confirm this association and determine
whether it is subgroup specific. It is noteworthy that the
IL-1α–889 polymorphism is functional: 2-2 homozy-
gotes showed an increased transcriptional activity com-
pared to 1-1 homozygotes and heterozygotes [28]. This
suggests that vulnerability to TLE may be related to
deregulation of the immune system, a hypothesis further
supported by the finding that three immune-related pro-
teins are down- or up-regulated – specifically the com-
plement factor 3, C3 – in brain of TLE patients [29].
Interestingly, the promoter region of C3 was found to be
very responsive to IL-1 [30]. 
Discrepancies have been reported in the association
studies between various epileptic syndromes and the IL-
1RA VNTR, which is described as a putative protein-
binding site and may influence gene expression [31]. For
the first time, in contrast to the research of Kanemoto et
al. [6] and despite weak statistical power, we observed
quite a strong positive association between this variant
and TLE: when compared to controls, TLE-HS– patients
displayed lower frequencies of allele 1 and genotype 1-1,
and higher frequencies of allele 2 and genotype 1-2 and
2-2. Tsai et al. reported an association between the same
polymorphism and FS, but in the opposite sense: the IL-
1RA allele 1 was significantly more frequent in FS chil-
dren than in controls [32]. Due to the small sample size,
we were unable to test the associations between IL-1RA
VNTR and the TLE-HS–-FC+ and TLE-HS–-FC– sub-
groups. Before proposing pathophysiological hypotheses
for these different associations, replication using larger
study groups is required.
Similarly, conflicting results were also reported for
IL-1β–511 SNP, which is an AP-2 binding site [33]. The
positive association with IL-1β–511 SNP observed in a
Japanese population [6] may be restricted to this ethnic
population. However IL-1β–511 allele 2 was signifi-
cantly more present in Caucasian patients with localisa-
tion-related epilepsy, such as TLE, lobe temporal
epilepsy, parieto-occipital epilepsy and multifocal
epilepsy [27]. Finally, the IL-1β–511 SNP was associat-
ed with FS only in Finnish [34] and German cohorts of
patients [35]. Very recently, Kauffman et al. assessed a
meta-analysis by pooling together all published studies
up to March 2007, regardless of the cohorts’ ethnicity.
They found a modest association between IL-1β–511
allele 2 and TLE-HS+ [36]. It is noteworthy that our
results also showed no significant association for the
1L-1β+3953 SNP, in accordance with previously pub-
lished studies [6, 15]. In contrast, the present negative
results for TLE-HS– and these two SNP must be inter-
preted with caution due to the weak power of associa-
tion detection. 
Finally, this present study, as well as some previous
related studies [1, 20, 21], were unable to replicate the
initial association between PDYN and TLE with a family
history for seizures [7]. However, a recently stratified
analysis, which pools four previous studies [1, 7, 20, 21],
showed a significant association [37]. Our non-obser-
vance of this association is possibly due to a lack of sta-
tistical power. Moreover, a study reported an association
between 32 autosomal dominant lateral temporal epilep-
sy index cases and PDYN [38]. 
Conclusion
The present study adds further data to the search for
susceptibility genes involved in TLE. Despite failure
to replicate most of the previously reported positive
associations, the publishing of our results is important
for future meta-analyses. Similarly, the positive asso-
ciation we report for the first time with IL-1α and IL-
1RA requires further analysis for confirmation of this
result.
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